DE602005022056D1 - Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind - Google Patents

Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind

Info

Publication number
DE602005022056D1
DE602005022056D1 DE602005022056T DE602005022056T DE602005022056D1 DE 602005022056 D1 DE602005022056 D1 DE 602005022056D1 DE 602005022056 T DE602005022056 T DE 602005022056T DE 602005022056 T DE602005022056 T DE 602005022056T DE 602005022056 D1 DE602005022056 D1 DE 602005022056D1
Authority
DE
Germany
Prior art keywords
immunosupppressive
modulation
effect
polypeptide sequences
viral proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005022056T
Other languages
English (en)
Inventor
Martial Renard
Marianne Mangeney
Thierry Heidmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Universite Paris Sud Paris 11
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Universite Paris Sud Paris 11
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR), Universite Paris Sud Paris 11 filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE602005022056D1 publication Critical patent/DE602005022056D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE602005022056T 2004-03-30 2005-03-30 Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind Active DE602005022056D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290838 2004-03-30
PCT/EP2005/003339 WO2005095442A1 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Publications (1)

Publication Number Publication Date
DE602005022056D1 true DE602005022056D1 (de) 2010-08-12

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022056T Active DE602005022056D1 (de) 2004-03-30 2005-03-30 Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind

Country Status (14)

Country Link
US (2) US8178657B2 (de)
EP (1) EP1732585B1 (de)
JP (1) JP5060284B2 (de)
CN (1) CN1961001B (de)
AT (1) ATE472334T1 (de)
AU (1) AU2005229411B2 (de)
BR (1) BRPI0509497B1 (de)
CA (1) CA2561376C (de)
DE (1) DE602005022056D1 (de)
ES (1) ES2347445T3 (de)
IL (1) IL178205A (de)
MX (1) MXPA06011272A (de)
WO (1) WO2005095442A1 (de)
ZA (1) ZA200608178B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
ATE538802T1 (de) 2005-03-30 2012-01-15 Viroxis Endogener retrovirus und proteine, kodiert durch env-gen, als target für die krebsbehandlung
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
BRPI1007376B1 (pt) 2009-01-09 2022-03-22 Centre National De La Recherche Scientifique Novos ligantes de ligação a receptores e seu uso na detecção de células de interesse biológico
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2012035369A1 (en) * 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
CN103957932B (zh) 2011-07-20 2017-06-23 梅里亚有限公司 包含最优化的猫白血病病毒包膜基因的重组猫白血病病毒疫苗
IN2014CN04927A (de) * 2011-12-07 2015-09-18 Viroxis S A S
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
WO2014195510A1 (en) * 2013-06-07 2014-12-11 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
EP3309178A4 (de) * 2015-06-11 2019-05-08 Keio University Fusionsprotein oder konjugiertes protein, träger zur intrazellulären abgabe, teilpeptid, zellmembran-permeationsverstärker, dna und vektor
JP7037486B2 (ja) * 2015-10-01 2022-03-16 エイムヴィオン・アクティエセルスカブ 医薬としてのヒト由来免疫抑制タンパク質およびペプチドの使用
CN111630060B (zh) * 2017-09-01 2024-01-23 盈珀治疗有限公司 用于在疾病的预防和/或治疗中使用的疫苗
CN113164623A (zh) 2018-09-18 2021-07-23 维恩维纽克公司 基于arc的衣壳及其用途
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
EP4277704A1 (de) 2021-01-13 2023-11-22 Viroxis Masern-hiv- oder masern-htlv-impfstoff

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
ATE128730T1 (de) 1988-12-13 1995-10-15 Univ Harvard Prototypische felv-isolate für die verwendung als krankheitsmuster oder impfstoffe.
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
WO2001031021A1 (en) * 1999-10-28 2001-05-03 Universite De Geneve Multiple sclerosis-related superantigen
WO2002047720A2 (en) 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
BRPI0509497B1 (pt) 2022-07-19
EP1732585B1 (de) 2010-06-30
ES2347445T3 (es) 2010-10-29
IL178205A0 (en) 2006-12-31
CA2561376C (en) 2016-06-21
US20080008683A1 (en) 2008-01-10
US8178657B2 (en) 2012-05-15
AU2005229411B2 (en) 2010-11-18
AU2005229411A1 (en) 2005-10-13
JP2008506357A (ja) 2008-03-06
ZA200608178B (en) 2008-10-29
WO2005095442A1 (en) 2005-10-13
EP1732585A1 (de) 2006-12-20
CA2561376A1 (en) 2005-10-13
US20120189647A1 (en) 2012-07-26
US8597657B2 (en) 2013-12-03
CN1961001B (zh) 2012-09-05
JP5060284B2 (ja) 2012-10-31
MXPA06011272A (es) 2007-04-17
WO2005095442A8 (en) 2006-11-02
CN1961001A (zh) 2007-05-09
BRPI0509497A (pt) 2007-09-11
IL178205A (en) 2015-05-31
ATE472334T1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
DE602005022056D1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
PT1685243E (pt) Linhas celulares aviárias imortalizadas para a produção de vírus
MX2018014228A (es) Proteina de union de albumina sérica de dominio unico.
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
WO2003104418A3 (en) RECONSTITUTED POLYPEPTIDES
MX2007007586A (es) Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
EP4019044A3 (de) Stabilisierte fusionsproteine der virusklasse i
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE486128T1 (de) Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
IL173952A0 (en) Anti-angiogenic peptides and pharmaceutical compositions based thereon
UA95446C2 (ru) Мутаци в генах oas1
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
MX2022014162A (es) Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
SG10201903142RA (en) Serpin fusion polypeptides and methods of use thereof
MX2010000232A (es) Metodos mejorados para la formacion de enlaces disulfuro.
WO2007089923A3 (en) Modifications of cst-ii for increased protein expression
DK1539221T3 (da) Transferrin-fusionsproteinbiblioteker
MX2023000373A (es) Proteinas de fusion de proteinas de la espicula de coronavirus estabilizadas.
DK1594991T3 (da) Fremgangsmåde til fremstilling af DNA-molekyler
WO2008038296A3 (en) Recombinant calcitonin fused to interleukin-2
MXPA05008925A (es) Ciclooxigenasa-3 humana y usos de la misma.
ATE527354T1 (de) Diabetogene epitope
ATE450546T1 (de) Impfstoffe mit ornithobakterium rhinotracheale- untereinheit